Archive

« Older Entries

argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Med... Thursday, December 29th, 2016
Breda, the Netherlands / Ghent, Belgium, December 29, 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for th [...]
LSP’s portfolio company Merus announces global strategic collaboration with Incyte Thursday, December 29th, 2016
LSP’s portfolio company Merus announces global strategic collaboration with Incyte to discover and develop bispecific antibodies   Upfront payment of $120 million plus equity investment of $80 million (at [...]
Kuros to acquire Xpand in an all-share strategic transaction to create a leading commercial stage orthobiologics company Monday, December 19th, 2016
Xpand’s first product MagnetOs, a novel orthobiologic, is approved for sale in the EU and has been filed for approval in the US Xpand has operations in the Netherlands including manufacturing and an experi [...]
Kiadis will start trial to treat children with severe blood disorder Thursday, December 15th, 2016
Amsterdam, The Netherlands, December 15, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative [...]
argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients Thursday, December 15th, 2016
Breda, the Netherlands / Ghent, Belgium, December 15, 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for th [...]
Curetis Acquires Real-Time qPCR Platform from Carpegen and Systec Tuesday, December 13th, 2016
Gyronimo Platform offers rapid, quantitative cartridge-based sample-to-answer molecular diagnostic testing Gyronimo to be fully integrated into Unyvero Platform and suite of products   Amsterdam, [...]
#investEU - Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform Monday, December 12th, 2016
European Investment Bank (EIB) provides EUR 10 million immediately, with a further EUR 15 million available upon meeting certain milestones Transaction is guaranteed by the European Fund for Strategic Invest [...]
LSP led a EURO 32 million investement in OxThera AB Friday, December 9th, 2016
Amsterdam, the Netherlands, December 9, 2016, OxThera AB, a Stockholm-based privately-held biopharmaceutical company, uses the proceeds to complete the Oxabact® development program for treatment of Primary hyperoxalu [...]
Hybrigenics enrolls a first patient in the United States in the clinical study of inecalcitol in acute myeloid leukemia patients unfit for chemotherapy Monday, November 28th, 2016
Paris, France, 28 November 2016 – Hybrigenics (FR0004153930 - ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments of prol [...]
Impacting patient lives with new diabetes drug approval Tuesday, November 22nd, 2016
Amsterdam, Munich, Boston, November 22, 2016 - LSP (Life Sciences Partners), the European life sciences investment group, today announces the FDA approval of SoliquaTM 100/33 for the treatment of adults with type 2 di [...]

« Older Entries

2018
2017
2016
2015
2014
2013
2012
back to archive overview

Archive

« Older Entries

argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental M... Thursday, December 29th, 2016
Breda, the Netherlands / Ghent, Belgium, December 29, 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for th [...]
LSP’s portfolio company Merus announces global strategic collaboration with Incyte Thursday, December 29th, 2016
LSP’s portfolio company Merus announces global strategic collaboration with Incyte to discover and develop bispecific antibodies   Upfront payment of $120 million plus equity investment of $80 million (at [...]
Kuros to acquire Xpand in an all-share strategic transaction to create a leading commercial stage orthobiologics company Monday, December 19th, 2016
Xpand’s first product MagnetOs, a novel orthobiologic, is approved for sale in the EU and has been filed for approval in the US Xpand has operations in the Netherlands including manufacturing and an experi [...]
Kiadis will start trial to treat children with severe blood disorder Thursday, December 15th, 2016
Amsterdam, The Netherlands, December 15, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative [...]
argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients Thursday, December 15th, 2016
Breda, the Netherlands / Ghent, Belgium, December 15, 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for th [...]
Curetis Acquires Real-Time qPCR Platform from Carpegen and Systec Tuesday, December 13th, 2016
Gyronimo Platform offers rapid, quantitative cartridge-based sample-to-answer molecular diagnostic testing Gyronimo to be fully integrated into Unyvero Platform and suite of products   Amsterdam, [...]
#investEU - Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform Monday, December 12th, 2016
European Investment Bank (EIB) provides EUR 10 million immediately, with a further EUR 15 million available upon meeting certain milestones Transaction is guaranteed by the European Fund for Strategic Invest [...]
LSP led a EURO 32 million investement in OxThera AB Friday, December 9th, 2016
Amsterdam, the Netherlands, December 9, 2016, OxThera AB, a Stockholm-based privately-held biopharmaceutical company, uses the proceeds to complete the Oxabact® development program for treatment of Primary hyperoxalu [...]
Hybrigenics enrolls a first patient in the United States in the clinical study of inecalcitol in acute myeloid leukemia patients unfit for chemotherapy Monday, November 28th, 2016
Paris, France, 28 November 2016 – Hybrigenics (FR0004153930 - ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments of prol [...]
Impacting patient lives with new diabetes drug approval Tuesday, November 22nd, 2016
Amsterdam, Munich, Boston, November 22, 2016 - LSP (Life Sciences Partners), the European life sciences investment group, today announces the FDA approval of SoliquaTM 100/33 for the treatment of adults with type 2 di [...]

« Older Entries

2018
2017
2016
2015
2014
2013
2012
back to archive overview